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Summary: The behaviour of the antifertilizing synthetic steroid RU 38486 towards human uterine progestin
receptor was investigated. RU 38486 competed in the same order of magnitude äs progesterone for the
[3H]R 5020 binding site of progestin receptor, whereas R 5020 was unable to compete against [3H]RU 38486.
This apparent contradiction could be explained by means of HPLC-chroniatography. HPLC-chromatography
with an anion exchange column (MonoQ, Pharmacia, Uppsala, Sweden) showed that [3H]RU 38486 forms
at least two stable complexes with uterine cytosol, on one hand with serum albumin, which presents almost
90% of bound radioactivity, and on the other hand with the two native progestin receptor forms, cor-
responding to 4 S and 8 S receptor forms in sucrose density gradient analysis.
Whether reduced binding of salt-activated RU 38486 receptor complexes to DNA-cellulose is due to reduced
activation is still uncertain and remains to be further investigated.
3H-Markiertes RU38486: Charakterisierung der Bindungseigenschaften in Cytosol aus Humanuterus
Zusammenfassung: Das synthetische Antifertilisierungshormon RU 38486 wurde hinsichtlich seiner Bindungs-
eigenschaften ani Progesteron-Rezeptor aus Humanuterus untersucht. RU 38486 kompetiert in der gleichen
Größenordnung wie Progesteron um den [3H]R 5020 Bindungsbezirk am Progesteron-Rezeptor, dagegen ist
kaltes R 5020 nicht in der Läge, [3H]RÜ 38486 aus seinen Bindungsbezirken im Uteruscytosol zu verdrängen.
Diese scheinbare Widersprüchlichkeit findet ihre Erklärung in der HPLC-Analyse der Bindungsverteilung
von [3H]RU 38486 in Uteruscytosol über eine MonoQ-Anionenaustauscher-Säule. [3H]RU 38486 bildet zwei
stabile Komplexe, zum einen mit Serum-Albumin, das etwa 90% der eingesetzten Radioaktivität bindet, zum
anderen mit den nativen Rezeptorformen, die in der Saccharose-Dichtegradienten-Analyse sich als 4 S- und
8 S-Rezeptorspecies darstellen.
Ob die verminderte Bindung salzaktivierter [3H]RU 38486-Rezeptor-Komplexe an DNA-Cellulose die Ursache
für die antigestagene Wirkung dieses synthetischen Steroids ist, bedarf weiterer Klärung.
Introduction progesterone in vivo, a property that is manifested
^„~~ ~^ , , ^ . , ~ intheinterruptionofthelutealphaseofthemenstrual
RU 38486 (structure see scheine 1) is the first
 cycle of ^ y pregnancy in women.
synthetic steroid possessmg a greater afnnity for the
progestin receptor in different animal target tissues There are some indications that the potent antagonist
than progesterone, but without exhibiting any agonist effect of RÜ 38486 is related to the essential bio-
progestin activity (1—3). Moreover, at large doses chemical Steps following progestin receptor
this steroid is capable of antagonizing the effects of occupancy which leäd to the biological response i. e.
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Schemel. Chemical structure and chemical nomenclature of
I RU 38486: 17ß-hydroxy-21-methyl-l lß(4-dimethylaminopheriyl)-19-nor-4,9 pregnadiene-20-yne-3^one
II Org2058: 16a-ethyM9-nor-21-hydroxy-4-pregnene-3,20-dione
III R 5020, promegestone: 17a, 21-dimethyl-19-nor-4,9-pregnadiene-3,20?dione
activation of the cytosolic progestin receptor and the
nuclear translocation. Like other antihormones (e. g.
some antiglucocorticoids which have been described
äs effective in vitro) (4-8) a possible mechanism of
the antifertility effect of RU 38486 could be in form-
ing a less stable complex with the cytosolic receptor,
which is unable to translocate properly into the nu-
cleus and trigger a progesterone response.
In view of the hypothesis described above, the follow-
ing investigation was undertaken. The aim was to
present a comparison of biochemical and physical
properties of the complexes which the human uterine
progestin receptor forms with the well-established
progestins progesterone, R 5020 and Org2058 on the
one hand and with RU 38486 (structure and
nomenclature see scheme 1) on the other hand.
Moreover, since binding to polyanions has been taken
äs a test for activation, the binding of the "salt-
activated" RU 38486- and R5020-progestin receptor
complexes to DNA-cellulose was compared.
Materials and Methods
Steroids and reagents
PH]R5020 (specific activity 3219 GBq/mmol), [3H]di-
hydrotestosterone (specific activity 1872 GBq/mmol),
[3H]aldosterone (specific activity 2960 GBq/mmol) and
unlabeled R 5020 were obtained from New England Nuclear
(Boston, USA). [3H]Cortisol (specific activity 1739 GBq/mmol),
[3H]Org2058 (specific activity 1554 GBq/mmol), [3H]dexa-
methasone (specific activity 3034 GBq/mmol) and unlabeled
Org2058 were purchased from the Radiochemical Centre
(Amersham UK). Radioinert and tritiated RU 38486 (specific
activity 1850 GBq/mmol) were a generous gift from Roussell-
Uclaf Laboratories. All these steroids were kept in benzene-
ethanol (85/15, vol/vol) at 4 °C and checked regularly for purity
by thin-layer chromatography.
Nonradioactive steroids for competition experiments were
obtained from Sigma Chemical Company (St. Louis, USA) and
not further purified. All solvents used were obtained from
Merck (Darmstadt, FRG) and were Uvasol grade.
Preparation of tissue samples
Human uteri were obtained after hysterectomy on the following
indications: myomata uteri and prolapsus uteri. Immediately
after hysterectomy an adequate sample was sent for histölogical
examination and the fest was washed in ice-cold saline to
remove mucous and blood. Then the tissue speeimens were
snap frözen in liquid nitrogen and stored at — 80 °C until use.
For cytosol preparation, uterine tissues were minced and
homogenized with an Ultra Tufrax at 0—4°C in ice-cold buffef
consisting of 10 mmol/1 KH2PO4, 10 rnmol/1 K2HPO4, 1.5
mmol/1 EDTA, 3 mmol/1 NaN3, glycerol, volume fraction 0.1,
pH 7.5. The homogenates were then centrifuged at 105000g at
4°C for 30 min. The supernatant was taken äs cytosol. Rat
liver and kidney cytosols from adrenalectomized feinale Wistar
rats (150—200g) were prepared in the same way äs the uterine
cytosol.
For HPLC (high performance liquid chromatography) cytosol
was prepared in ice-cold Tris/HCl-EDTA-buffer (20 mmol/1
Tris/HCl, 1.5 mmol/1 EDTA, pH 7.5).
Rate of association of the [3H]RU38486 uterine
receptor complex
Aliquots (0.1 ml) of uterine cytosol were incubated with 0.1 ml
aqueous Solutions of [3H]RÜ 38486 (final concentration 8
nmol/1) for various time intervals (äs indicated in flg. 1) at
4°C (total binding). Nonspecific binding was determined using
[3H]RU 38486 together with a 200-ibld molar excess of
unlabeled RÜ 38486 or R 5020 ünder identical incubation con-
ditions. All incubations were carried out in triplicate. At the
time intervals indicated, the unböund steroid was removed by
the additipn of 0.5ml aliquots dextran-coated charcoal suspen^·
sion (5 g/l Norit A, 0.5 g/l Dextran T400 in 10 mmoi/1 K2HPO4,
10 mmol/1 KH2PO4, 1.5 mmol/1 EDTA, 3 mmol/1 NaN3 and
glycerol, volume fraction 0.1, pH 7.5). The tubes were incubated
for 10 min at 4°C, followed by 10 min centrifugation at 1500g.
Supernatant (0.5ml) was placed in scintillation viäls, followed
by the addition of l Oral scintillation cocktail, then counted for
radioactivity.
Time-dependent dissociation of the [3H]RÜ38486
uterine receptor complex in the presence of
dextran-coated charcoal Suspension
Aliquots (0.1 ml) of human uterine cytosol were incubated
overnight at 4°C with 0.1 inl aqueous Solutions of
[3H]RÜ 38486 (final concentration 8 nmol/1) ± 200-fold excess
of unlabeled RU 38486 or R5020. After incubation for 16h at
4°C, 0.5ml of dextran-coated charcoal were added arid the
tubes were incubated under gentle shaking at 4°C for the
, following time intervals: t = 5, 15, 30, 45, 60, 90 min and 2,
4, 7h. This was followed by centrifugation and determmätion
of protein-bound radioactivity äs described above.
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Tit ra t ion of specific steroid binding sites
The binding constants and receptor capacities were determined
by multipoint titration using Scatchard analysis of the data (9).
The crude cytosol in phosphate/EDTA/NaN3/glycerol-buffer,
pH 7.5 was incubated for 16h at 0—4°C with various con-
centrations of 3H-labeled R5020 and RU 38486 over the r nge
which should saturate the receptors (0.5—8 nmol/1). Additional
cytosols were incubated with tritiated ligands in the presence
of a 200-fold excess of Uhlabeled ligands, in order to determine
the extent of nonspecific binding. Unbound ligand was removed
from receptor-associated ligand by using dextran-coated
charcoal.
Specifici ty of the receptor binding
The tubes for competition assays were prepared s follows: to
each tube 50 μΐ of 3H-labeled steroids (in phosphate/EDTA/
NaN3/glycerol-buffer, pH 7.5) were pipetted to give a final
concentration of 32 nmol/1. Then aliquots of 50 μΐ, containing
the various competitors (in phosphate/EDTA/NaN3/glycerol-
buffer, pH 7.5) at six different concentrations (10~10 - 10~5
mol/1) were added. Finally, to each tube 100 μΐ of cytosol
were added, and after gentle shaking the tubes were incubated
overnight at 4°C. The reactions were terminated by the addition
of 0.5 ml dextran-coated charcoal. After 10 min incubation
under gentle shaking the tubes were centrifuged for 10 min at
1500g. AJiquots (0.5ml) of the supernatant were transferred to
scintillation vials, and after addition of 10ml scintillatibn
cocktail they were counted for radioactivity. All determinations
were carried out in triplicate. The min"1-values were expressed
s % binding, taking the values for the tubes containing only
3H-ligands s 100%.
Serum binding
A pool of human pregnancy serum was stripped of endogeneous
steroids with dextran-coated charcoal. Aliquots of this serum
pool in a dilution of 1:10 with phosphate/EDTA/NaN3/
glycerol-buffer, pH 7.5 were incubated in triplicate for 60 min
at room temperature with 8 nmol/1 [3H]cortisol (for de-
termination of Cortisol binding globulin) or
[3H]dihydrotestosterone (for characterization of sex hormone
binding globulin) in the presence of increasing amounts of
the competitors listed in tab. l. After incubation the nbound
steroid was removed with dextran-coated charcoal. Aliquots of
the supernatant (0.5 ml) were then counted for radioactivity.
High performance liquid chromatography (HPLC)
Aliquots (2.5 ml) of human uterine cytosol (10—15 g/l) were
incubated with [3H]RU 38486, [3H]Org2058 or [3H]21-dehydro-
Org2058, respectively, t yield a final concentration of 32 nmol/1
(total binding), or together with a 200-fold molar excess of
unlabeled steroids (unspecific biijding) for 16 hours at 0—4°C.
For details of the synthesis of pH]16a-ethyl-19-nor-4-pregnene-
3,20-dione-21.al ([3H]21,dehydr -Qrg2058), see Heubner et al.
(10)andM «zetal.'(ll).
In another prepafation 10 mmpl/1 spdium m lybdate was added
to the homogenization buffer, and cytosol was incubated s
described above. Aliquots (1ml) of each incubation mixture
were heat activated for 30 min at 37 °C. Aliquots (500 ,μΐ) were
filtered through a Millex GV 0.22 μηι filter unit (Millipore,
Neu-Isenburg, F.R.G.), then injeeted onto the col mn.
Chtomatography was carried out on the Pharmacia HPLC
System (FPLC, Pharmacia, Uppsala, Sweden) fitted with a pre-
packed Mono Q col mn (high efficiency anion e*changer based
on monodisperse 10 μηι spheres, Pharmacia, Uppsala, Sweden).
The col mn was equilibrated in Tris/HCl-EDTA-buffer at 20 °C
and eluted at a flow rate pf 2 ml/min with a NaCl gradient to
l mol/1. Protein was monitored at 280 nm. Fractions (500
μΐ) were collected and radioactivity was measured by liquid
scintillation counting (Ready-Solv HP, Beckman, Munich,
F.R.G.).
Sucrose density gradient analysis
In 0.5 ml aliquots of all incubation mixtures, described in
the paragraph on HPLC, nbound steroid was removed with
dextran-coated charcoal. Aliquots of 0.2 ml were then layered
on top of 5 —30% linear sucrose gradients. The gradients were
centrifuged for 2.5h at 4°C at 404000g in a vertical rotor
(Beckman VTi65). The gradients were collected from the
bottom in 40 fractions. The gradients were standardized with
FITC-labeled bovine serum albumin (Mr = 67000) and FITC-
labeled IgG (MT = 150000) (Behring Werke, Marburg, F.R.G.).
Assay of receptor binding to DNA-cellulose
Cytosol fractions were incubated with 32 nmol/1 3H-labelled
steroid alone or with a 200-fold molar excess of the respective
unlabeled steroid for 16h. Activation of steroid receptor
complex was accomplished by adding a solution of 2 mol/1
NaCl in phosphate/EDTA/NaN3/glycerol-buffer, pH 7.5 to a
final concentration of 0.4 mol/I NaCl. This mixture was kept
for 40 min at 4°C. Now 100 μΐ activated cytosols were diluted
with 700 μΐ buffer and were incubated for 20 min at 4°C with
a DNA-cellulose pellet (Sigma Munich, F.R.G.) from 200 μΐ
of a 25% slurry of DNA-cellulose. After centrifugation for l
min at 2000g the samples were washed three times in cold
buffer and the final pellet was taken for determination of
radioactivity. All determinations were carried out in triplicate.
Protein determination
The protein concentrations were determined with the BioRad
protein assay kit (BioRad, Richmond, USA) using bovine
serum albumin s a Standard.
Results
Time studies of [3H]RU 38486 uptake show a rapid
increase in the amount of specific binding during the
first 4 to 5 hours (fig. 1). After Saturation, the amount
of specifically bound [3H]RU 38486 remains almost
constant up to 20 hours at 0—4°C. In contrast to
a thentic RU 38486, a 200-fold molar excess of
rionradioactive R 5020 did not reduce total
[3H]RU 38486 binding (especially during the first 4
hours).
The dissocialion of [3H]RU 38486 from the uterine
progestin receptor, measured by the displacement of
l beled steroid with dextran-coated charcoal treat-
ment at 0—4°C at various times, showed a biphasic
or two-component first order dissociation curve
(fig. 2). The [3H]RU 38486 dissociation rate constant
of the first, slower dissociating component, k_ t , was
linear with an k_! of 3.61 · 10~5 s"1 (tab. 1) or only
13% of k_2- The dissociation rate constant of the
second, more rapid component, k_2> wa$ 27.5 · 10~5
s^1. The biphasic dissociation curve was corrected
for "receptor" lability or inactivation by measuring
the specifically bound PH]RU 38486 in the absence of
nonradioactive steroid during the 0—4°C incubation.
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Fig. l Time course of association of [3H]RU 38486 with the
human uterine progestin binding protein.
O Total binding, O nonspecific binding ([3H]RU 38486
plus a 200-fold excess of RU 38486), D nonspecific
binding ([3H]RU 38486 plus a 200-fold excess of
R 5020).
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Fig. 2. Time course of dissociation of [3H]RU38486-progestin
binding protein complex of human Uterus in the pre-
sence of dextran-coated charcoal:
O total binding, O nonspecific binding ([3H]RU 38486
plus a 200-fold excess of RU 38486), D nonspecific
binding ([3H]RU 38486 plus a 200-fold excess of
R 5020).
Tab.l. Kinetic parameters of binding of [3H]labeled steroids
to human uterine progestin receptor.
Ligand
[3H]R5020
[3H]Progesterone
[3H]Cyproterone
acetate
[3H]RU 38486
k-,
(s'1)
3.6 · IO-5
21.3 · IO-5
17.8 - IO-5
3.61 - ΙΟ'5
Half- k_2
life (s-1)
(min)
320
54
65
321 27.5 - IO-5
Half-
life
(min)
42
There was no binding loss after a 4 h incubation, but
6% inactivation after 7h.
Moreover, it was the purpose of this study to compare
the kinetic properties of binding of [3H]RU 38486
with those of radiolabeled R 5020, progesterone and
cyproterone acetate, typical, well-characterized pro-
gestins. All these three steroids show, iii c ntrast to
RU 38486, single first order dissociation curves
(fig..3). [3H]R5020 forms more stable complexes with
uterine progestin receptor than radiolabeled pr -
gesterone or cyproterone acetate, which confirms
earlier observations (12, 13).
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Fig. 3. Determination of the halMife of the [3H]R 38486
(Q—D), [3H]R5020 (O—O), PH]progesterone
(0— ) and [3H]cyproterone acetate (Δ—Δ) binding
protein complexes of human uterine eytosol.
Figure 4 shows competition between various steroids
and labeled [3H]R5020 and [3H]RU 38486 for binding
to crude uterine cytosol.
As anticipated, Org2058, R5020, progesterone and
RU 38486 compete well with [3H]R5020 for the pro-
gestin binding sites of uterine cytosol. The order of
potency was: Org2058 > R5020 > progesterone >
RU 38486. Some competition can also be seen with
dexamethasone and cortisol. Most interesting, how-
ever, is the fact that neither progestins, androgens,
oestrogens nor glucocorticoids have any efFect on
[3H]RU 38486 binding.
Results concerning the specificity of binding to pro-
gestin, glucocorticoid, oestrogen and mineralo-
corticoid receptors in cytosol of typical target tissues
s well s to cortisol binding glob lin and sex
hormone binding glob lin in diluted pregnant serum
have been summarized in table2. THey are expressed
s relative binding affinities, i.e., s the relative con-
centration of test compound and radioinert ligand
' required to displace 50% of b nd radioligand from
its binding sites.
ι ι
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Competitor [mol/l] Competitor [mol/l]
Fig. 4. Specificity of the binding of [3H]RU 38486 and [3H]R5020 to the cytoplasmic progestin receptor in human uterus.
a) [3H]RU 38486 b) [3H]R5020
O RU 38486 Q R 5020
O R 5020 O Org2058
Δ Org2058 Δ Progesterone
D Progesterone Q RU 38486
A Cortisol Π Dexamethasone
V Dexamethasone A Cortisol
V Oestradiol
D Testosterone
+ Nortestosterone
Tab. 2. Relative binding affinites of various steroids for binding to human uterine progestin ([3H]R5020 or [3H]RU 38486) and
oestrogen ([3H]oestradiol) receptors, rat liver glucocorticoid receptor (pHJdexamethasone), rat kidney aldosterone receptor
(pH]aldosterone) s well s human corticosteroid binding globulin and sex hormone binding globulin. n.d. = not
determined
Ligand
RU 38486
Progesterone
R 5020
Org2058
Noftestosterone
Norethisterpne
Medroxyprogeste-
rone acetate
Chlormadinone
acetate
17a-Hydroxy-
progesterone
Dexamethasone
Cortisol
Oestradiol
Diethylstilb^
esti-ol
Testosterone
Dihydro-
testosterone
Aldosterone
Relative binding affmity values (%).
Progesterone Progesterone Gluco- Oestradiol Mineralo- Cortisol Sex hormone
receptor receptor corticoid receptor corticoid binding binding
receptor receptor globuline globuline
[3H]R5020 PH] [3H]Dexa- [3H] [3H] FH]Cortisol pHJdihydro-
RU 38486 methasone Oestradiol Aldosterone testosterone
25
40
100
350
95
70
115
25
0.8
3
<1
0.8
<0.1
0.9
0.9
0.2
100
<0.01
<0.01
<0.01
<0.01
n.d.
n.d.
n.d.
n.d.
<0.01
<0.01
n.d.
n.d.
<0.01
n.d.
n.d.
45
0.2
7
0.7
0.7
<0.1
29
n.d.
0.8
100
18
<0.01
<0.01
<0.01
<0,01
1.25
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
100
45
<0.1
<0.1
<0.01
70
10
53
27
n.d.
10
160
n.d.
40
400
70
<0.1
<0.1
17.5
n.d.
100
<0.01
13
<0.1
<0.1
<0.1
0.9
<0.1
<0.1
40
<0.01
100
<0.01
<0.01
10
0.3
6
<0.01
<0.01
<0.01
<0.01
8
50
<0.1
<0.1
<0.01
<0.01
<0.01
7
<0.01
n.d.
100
<0.01
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RU 38486 does not compete with [3H]di-
hydrotestosterone and [3H]cortisol for serum binding.
Moreover, this compound has no effect on
[3H]oestradiol binding, but shows a defmite influence
on [3H]R5020, [3H]dexamethasone and
[3H]aldosterone binding.
Figure 5 compares the titration of specific binding
sites in crude cytosol of human uterine tissue with
[3H]R5020 and [3H]RU 38486. Increasing cori-
centrations of labeled steroids were incubated with
cytosol either with or without a 200-fold molar excess
of radioinert R5020 or RU 38486 for 16 hours at
0—4°C, then assayed by the dextran-coated charcoal
technique to determine specific binding. Scatchard
analysis of these data gave only a linear plot for
[3H]R5020. For this particular steroid, the specific
R 5020 binding protein displayed comparable appar-
ent dissociation constants (Kd) under two different
dextran-coated charcoal incubation conditions: 2.08
• 10~9 mol/1 with 4h dextran-coated charcoal treat-
ment, and 2.6 · 10~9 mol/1 with 5min dextran-coated
charcoal stripping. The binding 'capacities were cal-
culated s 400 fmol/mg protein and 645 fmol/mg
protein, respectively. In contrast to these results,
[3H]RU 38486 was unable to saturate specific binding
sites of crude cytosol preparations up to a con-
centration of 8 nmol/1. This result shows a striking
similarity to those obtained by sucrose gradient cen-
trifugation and FPLC-chromatography s described
below.
500
g 250
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0 1 2 3 4 5 6 7
[ 3 H ] R U 3ΘΛΘ6 odded [nmol/l]
~ 1.0
Ό
c
l
° 0.5
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[ 3 H]R5020qdded [nmol/l]
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0 1 2 3 4 5 6 7 8
[ 3H]RU 38.486 added [nmol/l]
1.0
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0 1 2 3 4 5 6 7 8
[ 3 H]R 5020 added Cnmol/U
Fig. 5. Titration of [3H]RU 38486 or [3H]R5020 binding sites in cytosol from human Uterus. (For details see "Material arid
Methods").
a) [3H]R 38486
5 min dextran-coated
charcoal treatment
β [3H]RU 38486
O + 200-fold R 5020
B -l· 200-fold RU 38486
c) [3H]R5020
5min dextran-coated
charcoal treatment
• [3H]R5020
O + 200-fold R 5020
• + 200-fold R 38486
b) [3H]RU 38486
4h dextran-coated
charcoal treatment
• [3H]RU 38486
O -l· 200-fold R 5020
• + 200,foldRU 38486
d) [3H]R5020
4h dextran-coated
charcoal treatment
• [3H]R5020
O + 200-fold R 5020
• -h 200-fold RU 38486'
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Centrifugation of [3H]Org2Ö58 labeled human
myometrial cytosol through a 5 — 30% sucrose
gradient revealed two binding components which
sedimented in the 4 S and 8 S region (fig. 6). After
heat activation in the absence of molybdate only the
component in the 4 S region was detected. When the
cytosol preparation was labeled in vitro with [3H]21-
dehydro-Org2058 (a highly potent aftmity label,
which labels covalently the steroid binding site of
the progestin receptor by formation of intennediate
stable azomethine protein complexes (10, 11), and
investigated on a density gradient, two [3H]labelled
steroid macromolecule complexes with Sedimentation
rates of about 4 S and 8 S (in the cold and in the
presence of molybdate) were observed (fig. 7).
Nonradioactive Org2058 displaced [3H]21-dehydro-
Org2058 only from the 8 S binding protein, not from
the 4 S region.
Sucrose gradient centrifugation analysis of the
[3H]RU38486-labeled cytosol of human uterus
showed that the RU 38486 binding components mi-
grated äs two peaks sedimenting in the 4 S and 8 S
regions (fig. 8). A 200-fold molar excess of
nonradioactive RU 38486 or Org2058 reduced only
the 8 S peak; competition in the 4 S region was only
observed in the presence of RU 38486.
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Fig. 6. Sucrose density gradient analysis of [3H]Org2058 binding protein complexes on 10-35% linear sucrose density gradients
under low galt conditions with (a, b) and without (c, d) sodium molybdate at different incubation temperatures (a, c 4°C;
b, d 37 °C). Arrows indicate positions of 4 S and 8 S marker proteins.
·—· (3H]Org2058; O—Q + 200 foldOrg 2058.
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Fig. 7. Influence of incubation temperature (a, c 4°C; b, d 37 °C) and sodium molybdate (% b, with; c, d without) on the
Sedimentation profiles of [3H]21-dehydro Org2058 binding cdmponents of human uterine cytosol. Arrows indicate
positions of 4 S and 8 S marker proteins.
O—O [3H]21-dehydro-Org2058; Q—O + 200 foldOrg 2058.
The results in figure 9 and 10 illustrate HPLC of
differently labeled uterine progestin receptors on a
Mono Q anion exchange column. Free steroid was
eluted with the washing buffer. Independent of the
[3H]labelled steroid used, the specifically labeled pro-
teins eluted äs peak A and Ö (approximately 0.075
and 0.13 mol/1 NaCl). Peak B was not detectable
after heat activation (20 min, 37 °C) and is probably
identical with the 8 S bindirjg protein in sucrose den-
sity gradient analysis (data will be pubfrshed in detäil
elsewhere). The nonspecifically labeled protein (peak
C) eluting at 0.22 mol/1 NaCl was found in all pre-
parations and showed identical behaviour to serum
albumin (LC-partigen albumin immunodiffusion
plates, Behring-Werke, Marburg, F.R.G., fig.ll). A
comparison of [3H]Org2058 and [3H]RÜ 38486
labeled cytosol shows that the unspecifically bound
radioactivity, eluting with albumin (peak C), is more
than 10-fold higher for [3H]RU 38486 and represents
almost 90% of labeled protein. This radioactivity
cannot be suppressed by a 200-fold molar excess of
Org2058 but is reduced by about 30% with a 200-
fqld molar excess of RU 38486. In the case of
[3H]Org2058, however, unspecific binding, eluting
with albumin, represents approximately 10% of
boünd radioactivity and the overall unspecific biiid-
ing is less than 50% of boünd radioactivity.
The important biological property of any steroid
horrnone receptor is its äbility to bind DNA after
transformation. Therefore, the DNA-binding äbility
of the uterine progestin receptor was tested. Cytosols
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Fig. 8. Sedimentation profiles of [3H]RU 38486 binding proteins in cytosol of human uterine tissue under conditions described
under "Material and Methods". Arrows indicate positions of 4 S and 8 S marker proteins.
a, b with; c, d withput spdium molybdate; a, c 4°C; b, d 37 °C
O—O [3H]RU 38486; O—O + 200-fold RU 38486; D—D + 200-fold Org 2058.
were either labeled with 32 nmol/1 of [3H]R5020 or
[3H]RU 38486 with or without a 200-fold molar
excess of cold authentie ster ids. Bound radioactivity
and DNA-.cellulose binding were theii determined.
Table 3 shows that the complex of [3H]RU 38486 with
the progestin receptor is far less capable of binding
to DNA than the complex of progestin receptor
formed with [3H]R5020.
Tab. 3. Binding of steroid^progestiri receptov complexes to DNA-cellulose.
" The table comp res the binding of nonactivated and salt-activated complexes of progestin receptor with the known
progestins [3H]R5020 and [3H]Org2058 and complexes formed by [3H]RU 38486 in human uterine cytosol. For ex-
perimental details see "Materials and Methods".
R5020/Org2058
Total binding
+ 200-fold R5020/orOrg2058
4- 200-fold RU 38486
Bq/100 μΐ
cytosol
1670/1330
2'50/ 183
233/ 175
Binding to DNA-cellulose
non-
activated
67/33
42/11
25/10
salt-
activated
183/153
271 12
271 10
RU 38486
Bq/100 μΐ
cytosol
1170
1250
1020
Binding to DNA-cellulose
non-
activated
38
25
27
salt-
activated
75
25
27
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Fig. 9. Analysis of human uterine progestin receptor by HPLC on a MonoQ anion exchange column. High speed supernatant
which had been exposed to (a, b) [3H]Org2058 or (c, d) [3H]RU 38486 (32 nmol/1) with (D) or without (·) nonradioaetive
competitor was injected (500 μΐ) onto the column. Elution was performed s described under "Material and Methode".
Absorbance determinations at 280 nm and NaCl-gradients are shown by drawn lines.
a, b [3H]Org2058: O—O [3H]Org2058; D—D + 200-fold Org2058; O—O + 200-fold RU38486.
c, d [3H]RU 38486; O—O [3H]RU 38486; Q—O + 200-fold RU 38486, D—D + 200-fold Org2058
Discussion
These observations suggest that the highly potent
antifertilizing synthetic steroid RU 38486 (1-3)
forms at least two stable complexes with crude terine
cytosol, one apparently with albumin (peak C), and
the other with the native progestin receptor forms
(peaks A and B). This was clearly demonstrated by
HPLC-chromatography analysis of [3H]RU 38486
binding in uterine cytosol preparations.
The binding of [3H]RU 38486 to peak C, which has
a mobility identical to serum albumin, is of high
capacity. More than 90% of the added labeled steroid
was bound in this fraction, but only partial coinpeti-
tion f r binding was shown by utilabeled RU 38486,
and s anticipated, none was shown by Org2058
which is normally characterized by a lack of albumin
binding.
On the other hand unlabeled RU 38486 competed in
the same order of magnitude s progesterone for the
[3H]R5020 binding site of human uterine progestin
' receptor, indicating that this compound is a potent
progestin with respect to recentor binding. ,
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Fig. 10. Analysis of human uterine progestin receptor by HPLC
on a MonoQ anion exchange column. High speed
supernatant which had been exposed to [3H]21-
dehydro-Org 2058 (32 nmol/1) with (O) or without (©)
nonradioactive competitor was injected (500 μΐ) onto
the column. Elution was performed s described in
detail under "Material and Methods". Absorbance de-
termination at 280 nm and NaCl-gradients are shown
by drawn lines. a) with b) without molybdate
φ—β PH]21-dehydro-Org2058, —O +" 200-fold
Org2058
It seems obvious that the dimethylaminophenyl side
group on carbon 11 is responsible for the high ca-
pacity binding to serum albumin, bec use a free
electron pair can interact with free carboxy groups
of aspartic and glutamic acids of albumin, which act
s proton donors.
Fig. 1l. Analysis of various fraction numbers of HPLC elution
scheme (flg. 9 and 10) according to human serum
albumin contamination using LC-partigen albumin im-
munodiffusion plates (Behring Werke, Marburg,
F.R.G.). Only fraction no. 33 and 34 showed specific
albumin precipitation.
The question of whether RU 38486 exerts its
antihormonal action via the well established receptor
interactions or via modified actions cannot be an-
swered at the moment. Different modes of action,
such s interaction with carboxyl groups within or
apart the steroid binding side, changing the protein
conformation or sealing the binding site, could pro-
hibit either binding of naturally occurring steroids or
translation of the steroid receptor complexes into the
nucleus.
The reduced binding of salt-activated RU 38486-re-
ceptor complexes to DNA-cellulose is not nessarily
due to reduced activation but might also reflect the
distribution of binding equilibria between albumin
and receptor, thus reducing the availability of added
RU 38486 for the progestin receptor. On the other
band, it was demonstrated for a broad spectrum of
antiglucocorticoids that their antihormonal action is
due to the formation of labile cytoplasmic steroid
receptor complexes with a decreased or absent ca-
pacity for translocation (5,14—18). This phenomenon
is not general but tissue-specific. Carboxamide de-
rivatives of dexamethasone, for example, are
antiglucocorticoids in hepatoma cells (19), but are
potent agonists in human peripheral lymphocytes
(20).
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RU 38486 not only exerts pronounced antifertilising
effects, it is also a potent antiglucocorticoid (21). But
in contrast to other known antiglucocorticoids, like
carboxamide derivatives of dexamethasone,
RU 38486 forms stable complexes with the
glucocorticoid receptor protein under low
temperature conditions. These are destabilized only
after heat activation, thus prohibiting an effective
nuclear translocation (22).
To what extent an RU 38486-"albumin"-complex, äs
presented in this study, behaves like a receptor within
the target cell is unknown; its ability to translocate
into the nucleus and its possible nonspecific inter-
action with the receptor binding site on the level of
chromatin, thus acting äs an antihormone, is entirely
speculative but under investigation.
Finally, the high binding capacity of RU 38486 to
albumin could lead to an enpraious intra- and
extracellular accumulation of this steroid thus form-
ing a pool of steroid, which cannot be metabolized
but can be released slöwly. A long lasting hormonal
iinpulse of a single dose of RU 38486, äs demon-
strated in in-vivo experiments in rats, keeps the ani-
mal infertile for a long time.
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